RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.» Read More
Take a look at some of Tuesday's after-hours buzz: American Express, Vertex & more
The next takeout target in biotech? Here are three eligible candidates
Brian Sullivan and Dom Chu will list the top 40 cheapest stock picks from Goldman Sachs.
President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.
The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
Some of Wednesday's midday movers:
U.S. Treasury yields continued to rise on Tuesday amid data and expectations of Fed action.
Health care has been on a tear in 2014, and there is still room for upside. Wall Street analysts are focusing on the following four trends.
Some of Monday's midday movers:
Stocks cut losses to close mixed on Thursday as geopolitical tensions lingered ahead of consumer data.
U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.
Pfizer's vulnerability to cheap generics and its weak roster of experimental medicines will be on display Tuesday, when the company reports earnings.
The liver disease NASH is becoming more widespread, and the market for treatments may rival those for hepatitis C.
Uncertain how to put money to work in a market that continues to flirt with all-time highs? Jim Cramer has a few ideas. Ten of them.
Check out which companies are making headlines after the bell Tuesday.
Stocks fell, with the S&P 500 turning lower after rising to another record.
Vertex Pharmaceuticals' spike Tuesday had investors looking for the next breakout stock. UBS's Matt Roden likes these names.
A combination of Vertex drugs met the goals of two late-stage clinical trials in cystic fibrosis, setting the stage for Vertex to apply for approval.
Take a look at some of Tuesday's midday movers.